Health
PSMA-Directed Therapies and Diagnostics Expand Their Scope in Prostate Cancer – Targeted Oncology
With the emergence of therapies that target PSMA, a cell surface transmembrane protein that is overexpressed in most prostate cancer cells, particularly in castration-resistant…
The December 2020 approval of the first agent for positron emission tomography (PET) imaging of prostate-specific membrane antigen (PSMA)positive lesions in patients with prostate cancer, Gallium 68 PSMA-11 (Ga 68 PSMA-11), heralded an exciting new chapter in the diagnosis and treatment of metastatic castration-resistant prostate cancer (mCRPC). With the emergence of therapies that target PSMA, a cell surface transmembrane protein that is overexpressed in most prostate cancer cells, particularly…
Continue Reading